表面活性蛋白D与儿童急性呼吸衰竭中重症儿童ARDS、延长通气及死亡相关
该研究为BALI多中心前瞻性队列研究,纳入2周至17岁急性呼吸衰竭儿童,取插管当天或随后2天内首份血浆样本,用酶联免疫吸附试验测SP-D。350例中233例为儿童ARDS(PARDS)。校正年龄、PRISM-III及原发诊断后,SP-D升高与重症PARDS相关(OR=1.02;CI=1.01-1.04;P=.011),并与死亡(OR=1.02;CI=1.01-1.04;P=.004)、机械通气时间(P=.012)、PICU住院时间(P=.019)及最高氧合指数(P=.040)相关。SP-D还与年龄相关(rs=0.16,P=.002)。
要点
- 校正年龄、PRISM-III及原发诊断后,血浆SP-D升高与重症PARDS相关(OR=1.02;CI=1.01-1.04;P=.011)。
- 校正后SP-D升高与死亡相关(OR=1.02;CI=1.01-1.04;P=.004)。
- SP-D升高与机械通气时间(P=.012)、PICU住院时间(P=.019)及最高氧合指数(P=.040)相关。
- SP-D水平在不同原发诊断间存在差异(P<.001),并与年龄相关(rs=0.16,P=.002)。
- 350例急性呼吸衰竭患儿中233例为PARDS,SP-D取自插管当天或随后2天内首份血浆样本。
适用人群与场景
- 2周至17岁急性呼吸衰竭儿童,参与BALI多中心研究。
- 分析使用插管当天或随后2天内首份血浆样本的SP-D水平。
- 350例中233例为儿童ARDS(PARDS)。
研究设计与关键结果
- 研究类型为前瞻性队列研究,纳入350例急性呼吸衰竭患儿,其中233例为PARDS,SP-D用酶联免疫吸附试验测定。
- SP-D水平在不同原发诊断间存在差异(P<.001)。
- 校正年龄、PRISM-III及原发诊断后,SP-D升高与重症PARDS相关(OR=1.02;CI=1.01-1.04;P=.011)。
- 多变量分析显示SP-D升高与死亡相关(OR=1.02;CI=1.01-1.04;P=.004)。
- SP-D升高与机械通气时间(P=.012)、PICU住院时间(P=.019)及最高氧合指数(P=.040)相关。
- SP-D水平与年龄相关(rs=0.16,P=.002)。
证据类型、等级与局限
- 证据类型:前瞻性队列研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,未来研究将确定SP-D能否用于预测肺损伤程度或治疗反应,以及SP-D是否有助于识别PARDS内型。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Elevated surfactant protein D (SP-D) is a relatively specific indicator of lung injury and is associated with both acute and chronic lung disease in adults and respiratory distress syndrome in premature infants. The relationship between plasma SP-D and lung injury in children with acute respiratory failure is unclear.
RESEARCH QUESTION: Is plasma SP-D associated with lung injury or outcome in children with acute respiratory failure?
STUDY DESIGN AND METHODS: This was a prospective cohort study in children 2 weeks to 17 years of age with acute respiratory failure who participated in the BALI multi-center study. Analyses were done using SP-D levels in plasma from the first sample taken on either the day of intubation or one of the following 2 days. SP-D level was measured by enzyme-linked immunosorbent assay.
RESULTS: Plasma samples from 350 patients were used in the analysis; 233 had pediatric ARDS (PARDS). SP-D levels varied across primary diagnoses (P < .001). Elevated SP-D levels were associated with severe PARDS after adjusting for age, pediatric risk of mortality III (PRISM-III), and primary diagnosis (OR = 1.02; CI = 1.01-1.04; P = .011). Multivariable analyses also indicated that elevated SP-D levels were associated with death (OR = 1.02; CI = 1.01-1.04; P = .004), duration of mechanical ventilation (P = .012), PICU length of stay (P = .019), and highest oxygenation index (P = .040). SP-D levels also correlated with age (rs = 0.16, P = .002).
INTERPRETATION: Elevated plasma SP-D levels are associated with severe PARDS and poor outcomes in children with acute respiratory failure. Future studies will determine whether SP-D can be used to predict the degree of lung injury or response to treatment and whether SP-D is useful in identifying PARDS endotypes.
参考来源
- Dahmer MK, Flori H, Sapru A, et al. Surfactant Protein D Is Associated With Severe Pediatric ARDS, Prolonged Ventilation, and Death in Children With Acute Respiratory Failure. Chest. 2020. PMID: 32275979. doi:10.1016/j.chest.2020.03.041
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。